180 Life Sciences Funding Round

7/29/2025

Venture Equity

$425,000,000

Undisclosed

Company intends to use the net proceeds from the offering primarily for the purchase of ETH, as well as general corporate purposes and transaction expenses.

Private & Independent

Life Sciences

3000 El Camino Real, Building 4 200
Palo Alto, CA 94306
USA

Not Recorded

The company is a clinical stage biotechnology company headquartered in Palo Alto, California, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy. We have three different product development families that are focused on different diseases or medical conditions, and that target different factors, molecules or proteins, as follows: Anti-TNF (clinical; focusing on fibrosis and anti-tumor necrosis factor) SCAs (focusing on drugs which are synthetic cannabidiol or cannabigerol analogs), and Anti-TNF (preclinical; orally bioavailable).